NASDAQ:CBLICleveland BioLabs Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Cleveland BioLabs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.68 +0.15 (+9.80 %) (As of 04/3/2020 04:00 PM ET) Add Compare Share Today's Range$1.47Now: $1.68▼$1.9050-Day Range$1.52MA: $2.35▼$3.6052-Week Range$0.50Now: $1.68▼$5.00Volume257,456 shsAverage Volume413,694 shsMarket Capitalization$18.98 millionP/E RatioN/ADividend YieldN/ABeta1 ProfileAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. Its proprietary platform of toll-like immune receptor activators (TLR) has applications in radiation mitigation, oncology immunotherapy, and vaccines. The company's product candidate is entolimod, an immune-stimulatory agent, which is used as a medical radiation countermeasure and an immunotherapy for oncology and other indications. Its development programs include CBLB612, which is in preclinical studies, a synthetic molecule that activates the toll-like heterodimeric receptor 2/6 and stimulated white blood cell generation; and that has completed Phase II for treating myelosuppressive prophylaxis in patients with breast cancer receiving doxorubicin-cyclophosphamide chemotherapy. The company is also developing Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. Cleveland BioLabs, Inc. has strategic partnerships with the Cleveland Clinic and Roswell Park Cancer Institute. The company was founded in 2003 and is headquartered in Buffalo, New York.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Cleveland BioLabs. Previous Next 3.2 Community Rank Outperform VotesCleveland BioLabs has received 274 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCleveland BioLabs has received 154 “underperform” votes. (Add your “underperform” vote.)Community SentimentCleveland BioLabs has received 64.02% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Cleveland BioLabs and other stocks. Vote “Outperform” if you believe CBLI will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CBLI will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCleveland BioLabs does not currently pay a dividend.Dividend GrowthCleveland BioLabs does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cleveland BioLabs insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.88% of the stock of Cleveland BioLabs is held by insiders.Percentage Held by InstitutionsOnly 3.56% of the stock of Cleveland BioLabs is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Cleveland BioLabs is -8.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cleveland BioLabs is -8.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCleveland BioLabs has a P/B Ratio of 5.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.64 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Commercial physical research Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CBLI Previous Symbol CUSIPN/A CIK1318641 Webhttp://www.cbiolabs.com/ Phone716-849-6810Debt Debt-to-Equity RatioN/A Current Ratio3.87 Quick Ratio3.87Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$1.14 million Price / Sales16.65 Cash FlowN/A Price / Cash FlowN/A Book Value$0.32 per share Price / Book5.25Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-3,610,000.00 Net Margins-241.79% Return on Equity-93.20% Return on Assets-69.62%Miscellaneous EmployeesN/A Outstanding Shares11,300,000Market Cap$18.98 million Next Earnings Date5/20/2020 (Estimated) OptionableNot Optionable Receive CBLI News and Ratings via Email Sign-up to receive the latest news and ratings for CBLI and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:CBLI Rates by TradingView Cleveland BioLabs (NASDAQ:CBLI) Frequently Asked Questions How has Cleveland BioLabs' stock been impacted by COVID-19 (Coronavirus)? Cleveland BioLabs' stock was trading at $3.15 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CBLI stock has decreased by 46.7% and is now trading at $1.68. View which stocks have been mosted impacted by Coronavirus. When is Cleveland BioLabs' next earnings date? Cleveland BioLabs is scheduled to release its next quarterly earnings announcement on Wednesday, May 20th 2020. View our earnings forecast for Cleveland BioLabs. How were Cleveland BioLabs' earnings last quarter? Cleveland BioLabs, Inc. (NASDAQ:CBLI) announced its quarterly earnings results on Wednesday, November, 14th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter. The biotechnology company had revenue of $0.28 million for the quarter. Cleveland BioLabs had a negative return on equity of 93.20% and a negative net margin of 241.79%. View Cleveland BioLabs' earnings history. Has Cleveland BioLabs been receiving favorable news coverage? Press coverage about CBLI stock has been trending very negative recently, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Cleveland BioLabs earned a daily sentiment score of -3.3 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutCleveland BioLabs. Are investors shorting Cleveland BioLabs? Cleveland BioLabs saw a decline in short interest during the month of March. As of March 13th, there was short interest totaling 224,300 shares, a decline of 33.7% from the February 27th total of 338,500 shares. Based on an average trading volume of 904,100 shares, the short-interest ratio is currently 0.2 days. Currently, 5.7% of the company's shares are sold short. View Cleveland BioLabs' Current Options Chain. Who are some of Cleveland BioLabs' key competitors? Some companies that are related to Cleveland BioLabs include Eloxx Pharmaceuticals (ELOX), BIOQUAL (BIOQ), Bioanalytical Systems (BASI), HedgePath Pharmaceuticals (HPPI), US Stem Cell (USRM), Tenax Therapeutics (TENX), Geovax Labs (GOVX), Vitality Biopharma (VBIO), Protalex (PRTX), ALGAE TEC LTD/S (ALGXY) and Redpoint Bio (RPBC). What other stocks do shareholders of Cleveland BioLabs own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cleveland BioLabs investors own include Inovio Pharmaceuticals (INO), Tonix Pharmaceuticals (TNXP), Nektar Therapeutics (NKTR), Novavax (NVAX), Sorrento Therapeutics (SRNE), Actinium Pharmaceuticals (ATNM), Progenics Pharmaceuticals (PGNX), Corbus Pharmaceuticals (CRBP), Cidara Therapeutics (CDTX) and NovaBay Pharmaceuticals (NBY). Who are Cleveland BioLabs' key executives? Cleveland BioLabs' management team includes the following people: Dr. Yakov N. Kogan M.B.A., Ph.D., MBA, CEO & Interim Principal Financial Officer (Age 46)Dr. Langdon L. Miller, Pres & Chief Medical Officer (Age 65)Dr. Andrei V. Gudkov, Chief Scientific Officer (Age 63)Dr. Ann Lenich Hards Ph.D., Exec. VP of Regulatory AffairsDr. Andrei Purmal Ph.D., VP of Chemistry What is Cleveland BioLabs' stock symbol? Cleveland BioLabs trades on the NASDAQ under the ticker symbol "CBLI." How do I buy shares of Cleveland BioLabs? Shares of CBLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Cleveland BioLabs' stock price today? One share of CBLI stock can currently be purchased for approximately $1.68. How big of a company is Cleveland BioLabs? Cleveland BioLabs has a market capitalization of $18.98 million and generates $1.14 million in revenue each year. View additional information about Cleveland BioLabs. What is Cleveland BioLabs' official website? The official website for Cleveland BioLabs is http://www.cbiolabs.com/. How can I contact Cleveland BioLabs? Cleveland BioLabs' mailing address is 73 HIGH STREET, BUFFALO NY, 14203. The biotechnology company can be reached via phone at 716-849-6810 or via email at [email protected] This page was last updated on 4/4/2020 by MarketBeat.com StaffFeatured Article: How to invest using market indexes
